Loading...
01/10 00:34
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Aurora Cannabis has shown strong financial performance with a 37% increase in net revenue, positive free cash flow, and no cannabis business debt. The company is expanding internationally, particularly in favorable regulatory environments like Europe and Australia, and maintains high margins. While there are supply chain and competitive pressures, Aurora's strategic focus on operational excellence and profitability is reassuring. The Q&A session revealed confidence in managing supply challenges and sustaining margins, contributing to a positive outlook. Despite some uncertainties in competition and data, the overall sentiment is positive, suggesting a likely stock price increase.
Net Revenue $88.2 million, up 37% year-over-year, driven by a record $68.1 million from global medical cannabis segment.
Medical Cannabis Revenue $68.1 million, up 51% year-over-year, with 6% growth in Canada and 112% growth internationally.
Adjusted Gross Margin 65%, up 130 basis points year-over-year, resulting in record adjusted gross profit of $56 million.
Adjusted EBITDA $23.1 million, up 316% year-over-year, marking the ninth consecutive quarter of positive adjusted EBITDA.
Net Income $31.2 million, compared to a net loss of $17.1 million in the year-ago period.
Cash and Cash Equivalents $180.2 million, with no cannabis business debt.
Free Cash Flow Positive $27.4 million, compared to negative $4.7 million in the year-ago period.
Bevo Revenue $8.9 million, up from $7.3 million in the year-ago period, with adjusted gross margins of 40%, up from 28%.
Consumer Cannabis Revenue $9.9 million, down from $11.6 million in the year-ago period, with adjusted gross margins of 26%, down from 29%.
Cash Provided by Operating Activities $28.8 million, compared to cash used of $5.3 million in the year-ago period.
New Cultivars: Recently announced a series of new cultivars developed at Aurora Coast and grown across EU GMP and TGA GMP certified facilities.
Product Innovations: Latest innovations from Greybeard, San Rafael ’71 and Tasty’s brands were announced, focusing on premium science-driven offerings.
International Revenue Growth: International revenue increased 112%, surpassing Canadian medical cannabis for the second consecutive quarter, comprising 60% of global medical cannabis net revenue.
Expansion in Germany: Launched first German cultivated medical cannabis product under the brand IndiMed, manufactured locally.
Market Position in Australia: Maintaining the number two share in the Australian market with expanded distribution and broadened product portfolio.
Growth in Poland and UK: Both Poland and the UK generated record revenue this quarter.
Operational Efficiency: Achieved record adjusted gross margin at 65%, with improved efficiency in manufacturing operations.
Free Cash Flow: Generated $27 million in positive free cash flow, another record.
Strategic Shift to Medical Cannabis: Intentional pivot to align resources behind medical cannabis growth strategy and focus on high-margin opportunities outside North America.
Focus on Regulatory Environments: Positioning in Europe and Australia due to favorable regulatory environments for medical cannabis.
Regulatory Risks: The company acknowledges that the regulatory environments in Europe and Australia are more favorable for their business model compared to North America, where US federal legalization is taking longer than expected.
Competitive Pressures: Aurora Cannabis faces competitive pressures in the medical cannabis market, particularly in Germany and Australia, where they aim to maintain and grow their market share.
Supply Chain Challenges: The company emphasizes the importance of maintaining a consistent and reliable supply of high-quality products to pharmacy partners, indicating potential supply chain challenges in meeting growing demand.
Economic Factors: The overall growth in patient access to medical cannabis globally is seen as a positive trend, but economic fluctuations could impact consumer spending and investment in the cannabis sector.
Debt Management: While the cannabis operations are debt-free, the Bevo plant propagation business holds $57.9 million in nonrecourse debt, which could pose a risk if not managed properly.
Three-pronged strategy: Aurora Cannabis aims to leverage its EU GMP and TGA GMP manufacturing facilities, maintain medical cannabis margins through operational excellence, and achieve steady revenue and adjusted EBITDA contributions.
International Revenue Growth: International revenue increased by 112%, surpassing Canadian medical cannabis revenue for the second consecutive quarter, comprising 60% of global medical cannabis net revenue.
New Cultivars: Aurora announced new cultivars developed at Aurora Coast, enhancing product offerings and value creation through partnerships with other licensed producers.
Expansion in Germany: Aurora launched its first German cultivated medical cannabis product under the brand IndiMed, aiming to maintain a reliable supply to pharmacy partners.
Focus on Medical Cannabis: The company continues to prioritize high-margin medical cannabis opportunities, particularly in Europe and Australia.
Revenue Growth Expectations: Continued revenue growth across cannabis business, particularly in Europe and Australia, with expectations for seasonal increases in Bevo's plant propagation segment.
Margins and EBITDA: Margins are expected to hold strong with continued positive adjusted EBITDA.
Free Cash Flow: Positive free cash flow anticipated due to increased global medical cannabis revenue and disciplined working capital management.
Market Potential: The global medical cannabis market could exceed $5 billion in the next few years, with Aurora positioned to benefit significantly.
CapEx Discipline: Continued spend discipline on CapEx is expected to support improved operating cash use.
Free Cash Flow: Positive free cash flow was $27.4 million compared to a negative free cash flow of $4.7 million in the year ago period.
Cash and Cash Equivalents: We ended the quarter with $180.2 million in cash and cash equivalents and no cannabis business debt.
The earnings call presents a mixed bag: strong growth in medical cannabis and plant propagation segments, but declining consumer cannabis revenue and increased SG&A expenses. The Q&A highlights structural advantages in international markets but reveals uncertainties in regulatory environments and cash flow challenges. Despite positive adjusted net income and margin improvements, negative free cash flow and unclear guidance on regulatory impacts temper optimism. Without market cap details, a neutral stance is prudent, reflecting balanced positive and negative factors.
The earnings call reveals a strong financial performance with record medical cannabis revenue and improved margins. Despite lower consumer cannabis revenue, strategic focus on high-margin medical cannabis and international growth are promising. Positive cash flow and no cannabis business debt highlight financial health. The Q&A section reveals challenges in Europe but also demonstrates management's proactive strategies. While SG&A expenses are higher, they are partly one-time. Overall, the optimistic guidance for future EBITDA and market expansion suggests a positive sentiment, likely resulting in a stock price increase in the short term.
The earnings call highlighted strong financial performance with a 34% revenue growth and a significant increase in adjusted EBITDA. Despite a temporary decline in Poland, management provided optimistic guidance, particularly with international market expansion plans. The Q&A revealed confidence in overcoming competitive challenges and maintaining supply levels. Although management was vague on some specifics, the overall sentiment remained positive, especially with strong margins and no debt. Given these factors, a positive stock price movement is anticipated over the next two weeks.
Aurora Cannabis has shown strong financial performance with a 37% increase in net revenue, positive free cash flow, and no cannabis business debt. The company is expanding internationally, particularly in favorable regulatory environments like Europe and Australia, and maintains high margins. While there are supply chain and competitive pressures, Aurora's strategic focus on operational excellence and profitability is reassuring. The Q&A session revealed confidence in managing supply challenges and sustaining margins, contributing to a positive outlook. Despite some uncertainties in competition and data, the overall sentiment is positive, suggesting a likely stock price increase.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
